Details of Disease

General Information of Disease (ID: DISD8MTH)

• Disease Name: Erectile dysfunction
• Synonyms: male impotence; dysfunction, erectile; male sexual impotence; impotence; impotence, male; impotence, male sexual; sexual impotence, Male; sexual impotence (finding); male erectile Disorder; erectile dysfunction (disease); erectile dysfunction; sexual impotence
• Disease Class: HA00-HA01: Sexual dysfunction
• Definition: Persistent or recurrent inability to achieve or to maintain an erection during sexual activity.
• Disease Hierarchy:
  DIS7WG2P: Sexual dysfunction
  DISI0KH5: Penile disorder
  DISWD40R: Disease
  DISD8MTH: Erectile dysfunction
• ICD Code:
  ICD-11: ICD-11: HA01.1
  ICD-10: ICD-10: N48.4
  ICD-9: ICD-9: 302.72, 607.84
  Expand ICD-11: 'HA01.1
  Expand ICD-10: 'N48.4
  Expand ICD-9: 302.72,607.84
• Disease Identifiers:
  MONDO ID: MONDO_0005362
  MESH ID: D007172
  UMLS CUI: C0242350
  MedGen ID: 66879
  HPO ID: HP:0100639
  SNOMED CT ID: 860914002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alprostadil	DMWH7NQ	Approved	Small molecular drug	[1]
Avanafil	DM75CXN	Approved	Small molecular drug	[2]
Bremelanotide	DM20LIM	Approved	Small molecular drug	[3]
Moxisylyte	DMFCLYW	Approved	Small molecular drug	[4]
Rhucin	DM3ADGP	Approved	Small molecular drug	[5]
Tadalafil	DMJZHT1	Approved	Small molecular drug	[6]
Udenafil	DM1IQRP	Approved	Small molecular drug	[7]
Vardenafil	DMTBGW8	Approved	Small molecular drug	[8]
Yohimbine	DMJCP1Y	Approved	Small molecular drug	[9]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IN-001	DMN8LMH	Phase 3	NA	[10]
Relenza	DMADQGA	Phase 3	NA	[11]
BMS-223131	DMJUV6C	Phase 2	NA	[13]
FE-202767	DMDGZ1C	Phase 2	NA	[14]
UK-371800	DMI8795	Phase 1	Small molecular drug	[15]

This Disease is Treated as An Indication in 1 Drugs in Phase 3 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Sildenafil	DM4YDAJ	Phase 3 Trial	Small molecular drug	[12]

This Disease is Treated as An Indication in 8 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABT-724	DMDQVY4	Discontinued in Phase 2	Small molecular drug	[16]
DASANTAFIL	DMOWIGC	Discontinued in Phase 2	Small molecular drug	[17]
EMR-62203	DMIQRJW	Discontinued in Phase 2	NA	[18]
PT-14	DMYM9JL	Discontinued in Phase 2	NA	[19]
R-873	DMDOETQ	Discontinued in Phase 2	NA	[20]
SLX-2101	DM1J0YB	Discontinued in Phase 2	NA	[21]
UK-369003	DMHXRZF	Discontinued in Phase 1/2	Small molecular drug	[22]
FR-229934	DMT6R8I	Terminated	Small molecular drug	[23]

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aom-0890	DMT4I2W	Investigative	NA	[24]
CKD-533	DMH204Y	Investigative	NA	[24]
IP-1200	DMIX7CP	Investigative	NA	[25]
THIQ	DMP8LSF	Investigative	Small molecular drug	[26]
TLV-1	DMYTSOJ	Investigative	NA	[27]
TPN-729	DMW9G7H	Investigative	NA	[24]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 41 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD37	TTFCW29	Limited	Biomarker	[28]
CIT	TT3BKTU	Limited	Biomarker	[29]
DKK2	TTST5KX	Limited	Biomarker	[30]
GUCY1B1	TTLBYH1	Limited	Altered Expression	[31]
HMGCS2	TTS0EZJ	Limited	Biomarker	[32]
LIMK2	TTASMD8	Limited	Biomarker	[33]
MCHR2	TTS17MG	Limited	Genetic Variation	[34]
NPR1	TTM9IYA	Limited	Altered Expression	[35]
S1PR2	TTVSMOH	Limited	Biomarker	[36]
NOS1	TTZUFI5	moderate	Altered Expression	[37]
PDE3A	TT06AWU	moderate	Genetic Variation	[38]
ADRB3	TTMXGCW	Strong	Biomarker	[39]
AGER	TTMO9HF	Strong	Therapeutic	[40]
AGT	TT5C0UB	Strong	Biomarker	[41]
ARG2	TTV1AG6	Strong	Altered Expression	[42]
BAX	TTQ57WJ	Strong	Therapeutic	[43]
BCL2	TTFOUV4	Strong	Altered Expression	[44]
BCL2L1	TTRE6AX	Strong	Biomarker	[45]
CASP3	TTPF2QI	Strong	Biomarker	[44]
CNR1	TT6OEDT	Strong	Biomarker	[46]
EDN1	TTJR60Z	Strong	Biomarker	[47]
EDNRA	TTKRD0G	Strong	Biomarker	[48]
FABP4	TTHWMFZ	Strong	Biomarker	[49]
FSHR	TTZFDBT	Strong	Genetic Variation	[50]
GJA1	TT4F7SL	Strong	Biomarker	[51]
GRK2	TTAZ3MN	Strong	Altered Expression	[52]
HDAC3	TT4YWTO	Strong	Biomarker	[53]
IGFBP3	TTZHNQA	Strong	Therapeutic	[54]
IRF8	TTHUBNK	Strong	Genetic Variation	[55]
KDR	TTUTJGQ	Strong	Biomarker	[56]
MCAM	TTHRE05	Strong	Biomarker	[57]
NOS3	TTCM4B3	Strong	Genetic Variation	[58]
P2RY1	TTA93TL	Strong	Biomarker	[59]
P2RY2	TTOZHQC	Strong	Biomarker	[59]
PRKG1	TT7IZSA	Strong	Biomarker	[60]
PRL	TTJ2TSA	Strong	Biomarker	[61]
SHH	TTIENCJ	Strong	Biomarker	[62]
SIRT1	TTUF2HO	Strong	Therapeutic	[63]
VIP	TTGTWLF	Strong	Therapeutic	[64]
ROCK1	TTZN7RP	Definitive	Altered Expression	[65]
ROCK2	TTGWKQJ	Definitive	Altered Expression	[66]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC5A12	DTM301H	Strong	Genetic Variation	[34]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CES2	DETHCPD	Limited	Biomarker	[67]
DDAH1	DEY0TQC	Limited	Genetic Variation	[68]

This Disease Is Related to 29 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
COA8	OTOM9C4A	Limited	Genetic Variation	[69]
DDAH2	OT8Q40G2	Limited	Genetic Variation	[68]
EBPL	OT59J1GY	Limited	Biomarker	[70]
ESM1	OT331Y8V	Limited	Altered Expression	[71]
MLXIP	OT30UNI7	Limited	Biomarker	[72]
MYLIP	OTL0PFGV	Limited	Biomarker	[72]
NT5C1A	OTS7UF36	Limited	Biomarker	[73]
NUS1	OT4DQ82L	Limited	Biomarker	[74]
OPRPN	OT6K1ZD6	Limited	Altered Expression	[75]
PITX3	OTE2KT8P	Limited	Biomarker	[76]
SIM1	OTYKFPKZ	Limited	Biomarker	[34]
SMR3A	OT6NAJJI	Limited	Biomarker	[77]
ACOXL	OTW680HT	Strong	Genetic Variation	[55]
BAD	OT63ERYM	Strong	Therapeutic	[43]
CCND2	OTDULQF9	Strong	Biomarker	[78]
CDH13	OTD2CYM5	Strong	Genetic Variation	[34]
CFL1	OTT6D5MH	Strong	Therapeutic	[79]
DYNLL1	OTR69LHT	Strong	Therapeutic	[80]
GRAMD1B	OTCG1GX2	Strong	Genetic Variation	[55]
GRIN3A	OTQS9GYY	Strong	Biomarker	[81]
IRF4	OT1DHQ1P	Strong	Genetic Variation	[55]
MATN2	OTVDR68G	Strong	Genetic Variation	[34]
MYOCD	OTSJNHTH	Strong	Biomarker	[82]
NECTIN1	OTTE5ZR6	Strong	Biomarker	[83]
PTGFRN	OTBG4SA2	Strong	Genetic Variation	[50]
SHBG	OTPWU5IW	Strong	Genetic Variation	[84]
SP140	OTQZHFMT	Strong	Genetic Variation	[55]
TTC7A	OTDHLPQM	Strong	Genetic Variation	[50]
ALDH7A1	OTV57BZD	Definitive	Biomarker	[85]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1882).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7448).
• [3] Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4743).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7299).
• [7] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7320).
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 102).
• [10] Clinical pipeline report, company report or official report of Inpharma SA.
• [11] Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother. 2001 Jan;35(1):57-70.
• [12] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 206401.
• [13] Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance ... J Pharmacol Exp Ther. 2005 May;313(2):840-7.
• [14] ClinicalTrials.gov (NCT02545127) Trial Exploring the Efficacy and Safety of FE 202767.
• [15] Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6033-6.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019657)
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018967)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018868)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010143)
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020830)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022583)
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6558).
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014897)
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1304).
• [25] Clinical pipeline report, company report or official report of Immunologic.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1338).
• [27] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [28] Immunization associated with erectile dysfunction based on cross-sectional and genetic analyses.PLoS One. 2014 Oct 24;9(10):e111269. doi: 10.1371/journal.pone.0111269. eCollection 2014.
• [29] The mediating effect of family cohesion in reducing patient symptoms and family distress in a culturally informed family therapy for schizophrenia: A parallel-process latent-growth model.J Consult Clin Psychol. 2018 Jan;86(1):1-14. doi: 10.1037/ccp0000257. Epub 2017 Nov 27.
• [30] Pericyte-Derived Dickkopf2 Regenerates Damaged Penile Neurovasculature Through an Angiopoietin-1-Tie2 Pathway.Diabetes. 2018 Jun;67(6):1149-1161. doi: 10.2337/db17-0833. Epub 2018 Mar 20.
• [31] Soluble guanylate cyclase beta1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction.Int J Impot Res. 2006 Sep-Oct;18(5):432-7. doi: 10.1038/sj.ijir.3901461. Epub 2006 Mar 9.
• [32] Inactivation of the Ras/MAPK/PPAR signaling axis alleviates diabetic mellitus-induced erectile dysfunction through suppression of corpus cavernosal endothelial cell apoptosis by inhibiting HMGCS2 expression.Endocrine. 2019 Mar;63(3):615-631. doi: 10.1007/s12020-018-1810-2. Epub 2018 Nov 20.
• [33] Chronic administration of LIMK2 inhibitors alleviates cavernosal veno-occlusive dysfunction through suppression of cavernosal fibrosis in a rat model of erectile dysfunction after cavernosal nerve injury.PLoS One. 2019 Mar 14;14(3):e0213586. doi: 10.1371/journal.pone.0213586. eCollection 2019.
• [34] GWAS Identifies Risk Locus for Erectile Dysfunction and Implicates Hypothalamic Neurobiology and Diabetes in Etiology.Am J Hum Genet. 2019 Jan 3;104(1):157-163. doi: 10.1016/j.ajhg.2018.11.004. Epub 2018 Dec 21.
• [35] Differentially expressed angiogenic genes in diabetic erectile tissue - results from a microarray screening.Mol Genet Metab. 2012 Feb;105(2):255-62. doi: 10.1016/j.ymgme.2011.11.002. Epub 2011 Nov 10.
• [36] JTE-013 supplementation improves erectile dysfunction in rats with streptozotocin-induced type ?diabetes through the inhibition of the rho-kinase pathway, fibrosis, and apoptosis.Andrology. 2020 Mar;8(2):497-508. doi: 10.1111/andr.12716. Epub 2019 Oct 31.
• [37] TNF- antagonism with etanercept enhances penile NOS expression, cavernosal reactivity, and testosterone levels in aged rats.Can J Physiol Pharmacol. 2018 Feb;96(2):200-207. doi: 10.1139/cjpp-2017-0113. Epub 2017 Dec 20.
• [38] Molecular biological characterization of phosphodiesterase 3A from human corpus cavernosum.Chem Biol Interact. 1999 May 14;119-120:593-8. doi: 10.1016/s0009-2797(99)00074-5.
• [39] Mirabegron, A Selective 3-Adrenoceptor Agonist Causes an Improvement in Erectile Dysfunction in Diabetic Rats.Exp Clin Endocrinol Diabetes. 2021 Mar;129(4):296-302. doi: 10.1055/a-0869-7493. Epub 2019 Apr 12.
• [40] Evaluation of the effect of different doses of low energy shock wave therapy on the erectile function of streptozotocin (STZ)-induced diabetic rats.Int J Mol Sci. 2013 May 21;14(5):10661-73. doi: 10.3390/ijms140510661.
• [41] MyD88 overexpression deteriorates Ang-II-induced ED via upregulating MPO and COX2 and downregulating eNOS in the corpus cavernosum of rats.J Cell Biochem. 2019 May;120(5):7133-7146. doi: 10.1002/jcb.27987. Epub 2018 Nov 28.
• [42] Serum Arginase II level can be a novel indicator for erectile dysfunction in patients with vasculogenic erectile dysfunction: a comparative study.Int Urol Nephrol. 2018 Aug;50(8):1389-1395. doi: 10.1007/s11255-018-1921-y. Epub 2018 Jun 28.
• [43] PARP inhibition restores erectile function by suppressing corporal smooth muscle apoptosis in diabetic rats.J Sex Med. 2011 Apr;8(4):1072-82. doi: 10.1111/j.1743-6109.2010.02176.x. Epub 2011 Jan 14.
• [44] Engineered Mesenchymal Stem Cells Expressing Stromal Cell-derived Factor-1 Improve Erectile Dysfunction in Streptozotocin-Induced Diabetic Rats.Int J Mol Sci. 2018 Nov 23;19(12):3730. doi: 10.3390/ijms19123730.
• [45] Loss of anti-apoptotic genes in aging rat crura.J Urol. 2002 Nov;168(5):2296-300. doi: 10.1016/S0022-5347(05)64374-1.
• [46] Anandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB1 and vanilloid VR1 receptors.BJU Int. 2007 Dec;100(6):1385-90. doi: 10.1111/j.1464-410X.2007.07180.x. Epub 2007 Sep 10.
• [47] Role of endothelin receptors and relationship with nitric oxide synthase in impaired erectile response in diabetic rats.Andrologia. 2017 Mar;49(2). doi: 10.1111/and.12607. Epub 2016 May 4.
• [48] Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension.J Sex Med. 2008 Dec;5(12):2793-807. doi: 10.1111/j.1743-6109.2008.01009.x. Epub 2008 Sep 24.
• [49] Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor.Life Sci. 2007 Jan 23;80(7):699-708. doi: 10.1016/j.lfs.2006.10.022. Epub 2006 Nov 29.
• [50] Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer.Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1292-300. doi: 10.1016/j.ijrobp.2010.07.036.
• [51] Effect of platelet-derived growth factor-BB on gap junction and connexin43 in rat penile corpus cavernosum smooth muscle cells.Andrologia. 2019 Apr;51(3):e13200. doi: 10.1111/and.13200. Epub 2018 Nov 23.
• [52] G protein-coupled receptor kinase 2 inhibition improves erectile function through amelioration of endothelial dysfunction and oxidative stress in a rat model of type 2 diabetes.Asian J Androl. 2018 Sep 14;21(1):74-9. doi: 10.4103/aja.aja_69_18. Online ahead of print.
• [53] Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve-injured rats.J Sex Med. 2014 Jun;11(6):1442-51. doi: 10.1111/jsm.12522. Epub 2014 Mar 18.
• [54] shRNA constructs targeting IGFBP-3 alleviate age related erectile dysfunction in the rat.J Urol. 2014 Sep;192(3):990-6. doi: 10.1016/j.juro.2014.02.042. Epub 2014 Feb 24.
• [55] Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort.J Urol. 2012 Aug;188(2):514-20. doi: 10.1016/j.juro.2012.04.001. Epub 2012 Jun 15.
• [56] Arteriogenic erectile dysfunction alters protein expression within the cavernosal tissue in an animal model.J Sex Med. 2005 Mar;2(2):199-206. doi: 10.1111/j.1743-6109.2005.20229.x.
• [57] Correction of diabetic erectile dysfunction with adipose derived stem cells modified with the vascular endothelial growth factor gene in a rodent diabetic model.PLoS One. 2013 Aug 30;8(8):e72790. doi: 10.1371/journal.pone.0072790. eCollection 2013.
• [58] The association of Intron 4 VNTR and Glu298Asp polymorphisms of the nitric oxide synthetase 3 gene and vasculogenic erectile dysfunction in Turkish men.Syst Biol Reprod Med. 2019 Oct;65(5):383-389. doi: 10.1080/19396368.2019.1601792. Epub 2019 Apr 12.
• [59] Management of erectile function by penile purinergic p2 receptors in the diabetic rat.J Urol. 2009 May;181(5):2375-82. doi: 10.1016/j.juro.2009.01.002. Epub 2009 Mar 19.
• [60] Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1alpha.BJU Int. 2007 Jun;99(6):1488-94. doi: 10.1111/j.1464-410X.2007.06794.x. Epub 2007 Mar 12.
• [61] Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature.Ann Clin Biochem. 2005 Mar;42(Pt 2):153-9. doi: 10.1258/0004563053492784.
• [62] Peptide amphiphile nanofiber hydrogel delivery of sonic hedgehog protein to the cavernous nerve to promote regeneration and prevent erectile dysfunction.Nanomedicine. 2017 Jan;13(1):95-101. doi: 10.1016/j.nano.2016.08.032. Epub 2016 Sep 6.
• [63] Assessment of androgen replacement therapy for erectile function in rats with type 2 diabetes mellitus by examining nitric oxide-related and inflammatory factors.J Sex Med. 2014 Apr;11(4):920-929. doi: 10.1111/jsm.12447. Epub 2014 Jan 28.
• [64] Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study.BJU Int. 1999 Feb;83(3):274-9. doi: 10.1046/j.1464-410x.1999.00935.x.
• [65] Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.BJU Int. 2017 Feb;119(2):325-332. doi: 10.1111/bju.13691. Epub 2016 Nov 21.
• [66] Effect of HongJing I in Treating Erectile Function and Regulating RhoA Pathway in a Rat Model of Bilateral Cavernous Nerve Injury.Evid Based Complement Alternat Med. 2019 Sep 16;2019:1083737. doi: 10.1155/2019/1083737. eCollection 2019.
• [67] Intentional Exposure to Extreme Cold Temperature to Influence Shape and/or Weight and Its Association to Eating Disorder Pathology.Front Psychol. 2019 Nov 14;10:2539. doi: 10.3389/fpsyg.2019.02539. eCollection 2019.
• [68] DDAH1 and DDAH2 polymorphisms associate with asymmetrical dimethylarginine plasma levels in erectile dysfunction patients but not in healthy controls.Nitric Oxide. 2019 Nov 1;92:11-17. doi: 10.1016/j.niox.2019.08.001. Epub 2019 Aug 5.
• [69] Optimization of the APOP screener to predict functional decline or mortality in older emergency department patients: Cross-validation in four prospective cohorts.Exp Gerontol. 2018 Sep;110:253-259. doi: 10.1016/j.exger.2018.06.015. Epub 2018 Jun 20.
• [70] Evidence for ERP biomarkers of eating disorder symptoms in women.Biol Psychol. 2017 Feb;123:205-219. doi: 10.1016/j.biopsycho.2016.12.016. Epub 2017 Jan 3.
• [71] Significance of serum endothelial cell specific molecule-1 (Endocan) level in patients with erectile dysfunction: a pilot study.Int J Impot Res. 2017 Jul;29(4):175-178. doi: 10.1038/ijir.2017.19. Epub 2017 Apr 20.
• [72] The Changes of MicroRNA Expression in the Corpus Cavernosum of a Rat Model With Cavernous Nerve Injury.J Sex Med. 2018 Jul;15(7):958-965. doi: 10.1016/j.jsxm.2018.05.006.
• [73] M1 Macrophages Are Predominantly Recruited to the Major Pelvic Ganglion of the Rat Following Cavernous Nerve Injury.J Sex Med. 2017 Feb;14(2):187-195. doi: 10.1016/j.jsxm.2016.12.012.
• [74] Silencing Nogo-B receptor inhibits penile corpus cavernosum vascular smooth muscle cell apoptosis of rats with diabetic erectile dysfunction by down-regulating ICAM-1.PLoS One. 2019 Aug 23;14(8):e0220715. doi: 10.1371/journal.pone.0220715. eCollection 2019.
• [75] The opiorphin gene (ProL1) and its homologues function in erectile physiology.BJU Int. 2008 Sep;102(6):736-40. doi: 10.1111/j.1464-410X.2008.07631.x. Epub 2008 Apr 10.
• [76] Diagnostic Value of Plasma Pentraxin3- Level For Diagnosis of Erectile Dysfunction.Urol J. 2018 Jul 10;15(4):199-203. doi: 10.22037/uj.v0i0.3989.
• [77] hSMR3A as a marker for patients with erectile dysfunction.J Urol. 2007 Jul;178(1):338-43. doi: 10.1016/j.juro.2007.03.004. Epub 2007 May 23.
• [78] Localization of increased insulin-like growth factor binding protein-3 in diabetic rat penis: implications for erectile dysfunction.Urology. 2007 Nov;70(5):1019-23. doi: 10.1016/j.urology.2007.07.057.
• [79] Restoration of erectile function by suppression of corporal apoptosis, fibrosis and corporal veno-occlusive dysfunction with rho-kinase inhibitors in a rat model of cavernous nerve injury.J Urol. 2015 May;193(5):1716-23. doi: 10.1016/j.juro.2014.10.099. Epub 2014 Oct 27.
• [80] Antisense and short hairpin RNA (shRNA) constructs targeting PIN (Protein Inhibitor of NOS) ameliorate aging-related erectile dysfunction in the rat.J Sex Med. 2007 May;4(3):633-643. doi: 10.1111/j.1743-6109.2007.00459.x. Epub 2007 Apr 13.
• [81] Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology. 2009 Jun;34(7):1819-28. doi: 10.1038/npp.2009.4. Epub 2009 Mar 18.
• [82] In vivo tracking on longer retention of transplanted myocardin gene-modified adipose-derived stem cells to improve erectile dysfunction in diabetic rats.Stem Cell Res Ther. 2019 Jul 16;10(1):208. doi: 10.1186/s13287-019-1325-7.
• [83] Nectin-4 mutations causing ectodermal dysplasia with syndactyly perturb the rac1 pathway and the kinetics of adherens junction formation.J Invest Dermatol. 2014 Aug;134(8):2146-2153. doi: 10.1038/jid.2014.119. Epub 2014 Feb 27.
• [84] Blood pressure, antihypertensive medication use, and risk of erectile dysfunction in men with type I diabetes.J Hypertens. 2019 May;37(5):1070-1076. doi: 10.1097/HJH.0000000000001988.
• [85] The Phosphodiasterase 5-Inhibitors (PDE-5i) for Erectile Dysfunction (ED): A Therapeutic Challenge For Psychiatrists.Curr Drug Targets. 2018;19(12):1366-1377. doi: 10.2174/1389450118666170215164747.